0001209191-11-042167.txt : 20110803
0001209191-11-042167.hdr.sgml : 20110803
20110802203338
ACCESSION NUMBER: 0001209191-11-042167
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: Rule 506
FILED AS OF DATE: 20110803
DATE AS OF CHANGE: 20110802
EFFECTIVENESS DATE: 20110803
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Trimel Pharmaceuticals Corp
CENTRAL INDEX KEY: 0001527246
IRS NUMBER: 000000000
STATE OF INCORPORATION: A6
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-163870
FILM NUMBER: 111005065
BUSINESS ADDRESS:
STREET 1: 2488 DUNWIN DRIVE
CITY: MISSISSAUGA
STATE: A6
ZIP: L5L 1J9
BUSINESS PHONE: 1 416 679 0771
MAIL ADDRESS:
STREET 1: 2488 DUNWIN DRIVE
CITY: MISSISSAUGA
STATE: A6
ZIP: L5L 1J9
D
1
primary_doc.xml
X0704
D
LIVE
0001527246
Trimel Pharmaceuticals Corp
2488 Dunwin Drive
Mississauga
A6
ONTARIO, CANADA
L5L 1J9
1 416 679 0771
ONTARIO, CANADA
None
None
Corporation
true
2009
Bruce
D.
Brydon
2488 Dunwin Drive
Mississauga
A6
ONTARIO, CANADA
L5L 1J9
Executive Officer
Director
Kenneth
G.
Howling
2488 Dunwin Drive
Mississauga
A6
ONTARIO, CANADA
L5L 1J9
Executive Officer
Mark
L.
Thompson
2488 Dunwin Drive
Mississauga
A6
ONTARIO, CANADA
L5L 1J9
Executive Officer
Rolf
Reininghaus
2488 Dunwin Drive
Mississauga
A6
ONTARIO, CANADA
L5L 1J9
Executive Officer
Director
Robert
Podruzny
2488 Dunwin Drive
Mississauga
A6
ONTARIO, CANADA
L5L 1J9
Director
Douglas
Deeth
2488 Dunwin Drive
Mississauga
A6
ONTARIO, CANADA
L5L 1J9
Director
Larry
Davis
2488 Dunwin Drive
Mississauga
A6
ONTARIO, CANADA
L5L 1J9
Director
Stephen
Gregory
2488 Dunwin Drive
Mississauga
A6
ONTARIO, CANADA
L5L 1J9
Director
James
Butler
2488 Dunwin Drive
Mississauga
A6
ONTARIO, CANADA
L5L 1J9
Director
Jeffrey
Sherman
2488 Dunwin Drive
Mississauga
A6
ONTARIO, CANADA
L5L 1J9
Director
Eugene
Melnyk
Beach House, Crane
St. Philip
C8
BARBADOS
BB18079
Promoter
Pharmaceuticals
Decline to Disclose
- 06
false
2011-07-14
true
true
true
true
true
Securities were issued in exchange for previously issued securities of Trimel BioPharma Holdings Inc. pursuant to an amalgamation agreement dated March 2, 2011 (as amended on each of June 14, 2011 and June 30, 2011).
0
12026355
6847846
5178509
"Total Remaining to be Sold" includes amounts related to common shares of filer to be issued upon exercise of warrants included in units issued on July 14, 2011.
false
16
0
0
0
false
Trimel Pharmaceuticals Corp
/s/ Kenneth G. Howling
Kenneth G. Howling
Chief Financial Officer
2011-08-02